- Home
- TXMD vs NEA Comparison
TXMD vs NEA Comparison
Compare TXMD & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TXMD | NEA |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3M | 3.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TXMD | NEA |
|---|---|---|
| Price | $1.77 | $11.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.8K | ★ 803.4K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.23% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $2,796,000.00 | N/A |
| Revenue This Year | $427.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $259.70 | ★ N/A |
| Revenue Growth | ★ 75.19 | N/A |
| 52 Week Low | $0.70 | $9.20 |
| 52 Week High | $2.44 | $11.37 |
Technical Indicators
Market Signals| Indicator | TXMD | NEA |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 51.06 |
| Support Level | $1.64 | $11.46 |
| Resistance Level | $1.83 | $11.65 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 44.14 | 42.97 |
Price Performance
Historical ComparisonAbout TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.